PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
31.77%
Cash & equivalents growing 31.77% while TRVN's declined -2.91%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
31.77%
Below half of TRVN's -2.91%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.02%
≥ 1.5x TRVN's 4.71%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
13.80%
Below half TRVN's -2.36%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.28%
Below half of TRVN's -2.03%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.41%
≥ 1.5x TRVN's 4.22%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
2.77%
Less than half of TRVN's 137.11%. David Dodd sees a more disciplined AP approach or lower volume.
1023.68%
Above 1.5x TRVN's 3.08%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-1.85%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
1.86%
Less than half of TRVN's 309.09%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.95%
Above 1.5x TRVN's -2.75%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of TRVN's 108.43%. David Dodd sees far fewer liability expansions relative to competitor.
28.57%
Above 1.5x TRVN's 1.91%. Michael Burry suspects heavy new equity expansion or dilution.
-2.84%
Similar yoy to TRVN's -2.76%. Walter Schloss sees parallel earnings retention vs. competitor.
100.00%
Similar yoy to TRVN's 100.00%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
34.98%
Below half TRVN's -6.42%. Michael Burry sees potential underperformance in building shareholder capital.
31.41%
≥ 1.5x TRVN's 4.22%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-15.85%
Above 1.5x TRVN's -2.06%. Michael Burry sees a major jump. Investigate leverage rationale.
-32.66%
Less than half of TRVN's 2.97%. David Dodd sees better deleveraging or stronger cash buildup than competitor.